---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Limitations of current therapies"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Limitations of current therapies. Topics: Summary: HLA restriction of tebentafusp and absence of approved therapy for HLA-A∗02:01-negative disease; Summary: response, survival, and toxicity with immune checkpoint inhibitors; Summary: scope and risks of liver-directed therapy; Summary: outcomes with chemotherapy and earlier targeted therapies; 18 further topics. 22 evidence topics quoted from 24 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Limitations of current therapies

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Limitations of Current Therapies

<a id="topic-2.2.2.1.6-1"></a>

### Summary: HLA restriction of tebentafusp and absence of approved therapy for HLA-A∗02:01-negative disease

Tebentafusp, the only FDA-approved systemic therapy for metastatic uveal melanoma, is approved by the FDA and the EMA as first-line systemic treatment for HLA-A∗02:01-positive patients, and only approximately 45% of individuals in the United States and Europe are HLA-A∗02:01-positive. HLA-A∗02:01-negative patients “continue to lack an established standard of care” and comprised 49% of individuals prescreened in the tebentafusp trial. There is no consensus on first-line systemic therapy for HLA-A∗02:01-negative patients; their current options are immune checkpoint inhibitors, “which are not specifically approved for mUM”, and participation in clinical trials, and the National Cancer Institute states that no effective method of systemic treatment has been identified for metastatic ocular melanoma. Within its eligible population, tebentafusp produced a 5-year overall survival rate of 16% versus 8% in the control group with an 11% overall response rate, almost all treated patients eventually progressed, and Piperno-Neumann et al. state that “a high unmet need remains”. Tebentafusp requires weekly intravenous administration with observation periods at initiation and inpatient monitoring for the first 3 to 4 infusions because of the risk of cytokine release syndrome, which occurred in 89% of tebentafusp-treated patients.

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext); [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802); [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/); [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq); [García-Mulero et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10732647/); [CADTH reimbursement recommendation, tebentafusp (2023)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/PC0290/1148?inline=1); [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

<a id="topic-2.2.2.1.6-2"></a>

### Summary: response, survival, and toxicity with immune checkpoint inhibitors

With PD-1 inhibitors in uveal melanoma, the objective response rate is below 5%, median progression-free survival 3 months, and 1-year overall survival approximately 50%. A meta-analysis reported a pooled objective response rate of 9.2% (4.1% for anti-CTLA4, 7.1% for anti-PD(L)1, and 13.5% for anti-CTLA4 plus anti-PD1) and a median overall survival of 11.5 months; a second meta-analysis of 1414 patients reported response rates of 3.4% with single-agent and 12.4% with dual checkpoint inhibition and median overall survival of 9.8 and 16.3 months. In two phase 2 trials of nivolumab plus ipilimumab, objective response rates were 11% and 18% and median overall survival 12 and 19 months. Pham et al. conclude that checkpoint inhibitors have limited efficacy in metastatic uveal melanoma. Dual checkpoint inhibition adds toxicity: in the 64 participants with metastatic uveal melanoma in CheckMate 401, 64% had grade 3-4 treatment-related adverse events and 30% discontinued; grade 3-4 treatment-related adverse events occurred in 40% of patients in one phase 2 trial and severe treatment-related adverse events in 39.1% of patients in a German series; 34 of 89 patients in a retrospective study across 14 academic medical centers discontinued for toxicity; and treatment-related discontinuation was 23% with nivolumab plus ipilimumab versus 2%-5% with pembrolizumab, without a clear survival advantage for the combination.

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Pham et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37199712/); [Yamada et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10991441/); [Pelster et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8257877/); [Heppt et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6854774/); [Najjar et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7319717/)

<a id="topic-2.2.2.1.6-3"></a>

### Summary: scope and risks of liver-directed therapy

Liver-directed therapy treats liver metastases alone: percutaneous hepatic perfusion “does not address extrahepatic disease”. Most patients have multifocal and small liver metastases, and around 10% are eligible for local therapy, with perioperative mortality and morbidity after surgery of approximately 2% and 14%. The FOCUS study of melphalan percutaneous hepatic perfusion enrolled patients with liver tumor involvement of up to 50% and excluded those with moderate or severe cirrhosis, portal hypertension, or NYHA II-IV status; grade 3 and 4 treatment-emergent adverse events occurred in 81.1% of patients, including thrombocytopenia in 54.7%, and 17.9% discontinued treatment because of them. In an earlier randomized trial, four deaths were attributed to melphalan percutaneous hepatic perfusion, and median overall survival did not differ significantly between arms (10.6 versus 10.0 months). Isolated hepatic perfusion is non-repeatable and carries higher morbidity and mortality, and in the SCANDIUM trial the primary endpoint was not met (24-month overall survival 46.5% versus 29.5%, P=0.12). Adding ipilimumab plus nivolumab to percutaneous hepatic perfusion raised grade 3-4 treatment-related adverse events from 41% to 82%.

Source: [van den Hoek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41785896/); [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Zager et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11249544/); [Hughes et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185532/); [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/)

<a id="topic-2.2.2.1.6-4"></a>

### Summary: outcomes with chemotherapy and earlier targeted therapies

Response rates to chemotherapy are below 10% regardless of the cytotoxic agent, with no demonstrated overall survival benefit over best supportive care. Across 40 studies, complete or partial remissions occurred in 39 of 841 patients (4.6%), with no responses in 22 of the 40 studies. In randomized trials, no objective responses were observed with temozolomide or dacarbazine and median overall survival was 9.1 months, the objective response rate with placebo plus dacarbazine was 0%, and median overall survival with temozolomide or dacarbazine was 7.3 months in another trial. In a literature review, systemic treatment was associated with response rates below 10%, median progression-free survival of 1.8-7.2 months, and median overall survival of 5.2-19.0 months, and pooled survival fell from 52% at 1 year to 25% at 2 years and 13% at 3 years. Among earlier targeted agents, selumetinib plus dacarbazine did not significantly improve progression-free survival over placebo plus dacarbazine, the response rate to MEK inhibitors averaged 2.5% (range 0 to 14%), and 3% of 153 participants achieved a partial response with the protein kinase C inhibitor AEB071. A standard of care has not been defined despite numerous phase 2 studies.

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Buder et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3892799/); [Carvajal et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4249701/); [Carvajal et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29528792/); [Luke et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7055933/); [Rantala et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6887637/); [Steeb et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/30205280/); [Piperno-Neumann et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32029634/); [Khoja et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31150059/)

<a id="topic-2.2.2.1.6-5"></a>

### Response and survival with systemic treatment: guideline summary of a literature review

> “According to findings from a literature review, systemic treatment of metastatic UM was associated with low response rates (<10%), low median PFS (1.8-7.2 months) and OS (5.2-19.0 months).”
> “Few prospective studies have been published on this rare cancer, especially randomised controlled trials.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.6-6"></a>

### No consensus on first-line systemic therapy for HLA-A∗02:01-negative disease

> “There is no consensus on first-line systemic therapy in HLA-A∗02:01-negative patients with metastatic UM.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.6-7"></a>

### Unmet need and treatment options for HLA-A∗02:01-negative patients after the five-year tebentafusp analysis

> “Before tebentafusp, mUM lacked specifically approved therapies. Even with the progress reported in this study, a high unmet need remains.”
> “For these patients, current treatment options include immune checkpoint inhibitors, which are not specifically approved for mUM, and participation in clinical trials.”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.1.6-8"></a>

### Proportion of patients eligible for tebentafusp by HLA-A∗02:01 status

> “However, only ~45% of individuals in the United States and Europe are HLA-A*02:01–positive, making only a subset of patients potentially eligible for this treatment.”

Source: [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/)

<a id="topic-2.2.2.1.6-9"></a>

### No defined standard of care after numerous phase 2 studies

> “Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM).”

Source: [Khoja et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31150059/)

<a id="topic-2.2.2.1.6-10"></a>

### Decline in pooled overall survival from 1 to 3 years across treatment modalities

> “The median OS was 1.07 years (95% CI: 1.00–1.13), but the survival rate decreased rapidly from 52% (95% CI: 50–54) at 1 year to 25% (95% CI: 23–26) at 2 years, and 13% (95% CI: 12–15) at 3 years (Table 1 ).”

Source: [Rantala et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6887637/)

<a id="topic-2.2.2.1.6-11"></a>

### Limited efficacy of immune checkpoint inhibitors in meta-analysis

> “ICIs have limited efficacy in mUM and a recommendation for their use must consider the balance of benefit and risk for individual patients if no other options are available.”

Source: [Pham et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37199712/)

<a id="topic-2.2.2.1.6-12"></a>

### Pooled response and survival with immune checkpoint inhibitors in 1414 participants

> “A random-effect model meta-analysis with generic inverse-variance was conducted, and 36 articles representing 41 cohorts of 1414 patients with metastatic uveal melanoma were included.”
> “Compared to single-agent ICI, dual ICI led to better ORR (single-agent: 3.4% [95% CI 1.8–5.1]; dual-agent: 12.4% [95% CI 8.0–16.9]; P < 0.001), DCR (single-agent: 29.3%, [95% CI 23.4–35.2]; dual-agent: 44.3% [95% CI 31.7–56.8]; P = 0.03), and OS (single-agent: 9.8 months [95% CI 8.0–12.2]; dual-agent: 16.3 months [95% CI 13.5–19.7]; P < 0.001).”

Source: [Yamada et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10991441/)

<a id="topic-2.2.2.1.6-13"></a>

### Toxicity of nivolumab plus ipilimumab in the uveal melanoma subgroup of CheckMate 401: guideline summary

> “In the subgroup of 64 patients with metastatic UM from CheckMate 401, ORR was 9% and median OS was 15 months; nivolumab–ipilimumab was associated with 64% grade 3-4 TRAEs, leading to discontinuation in 30% of patients.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.6-14"></a>

### Grade 3 to 4 treatment-related adverse events with nivolumab plus ipilimumab

> “Forty percent of patients experienced a grade 3-4 treatment-related adverse event.”

Source: [Pelster et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8257877/)

<a id="topic-2.2.2.1.6-15"></a>

### Treatment discontinuation for toxicity with nivolumab plus ipilimumab

> “Overall, 82 (92%) of patients discontinued treatment, 34 due to toxicity and 27 due to progressive disease.”
> “Dual checkpoint inhibition yielded higher response rates than previous reports of single-agent immunotherapy in patients with mUM, but the efficacy is lower than in metastatic CM.”

Source: [Najjar et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7319717/)

<a id="topic-2.2.2.1.6-16"></a>

### Severe treatment-related adverse events with combined checkpoint blockade

> “Regarding safety, 39.1% of treated patients experienced a severe, treatment-related adverse event according to the CTCAE criteria (grade 3: 37.5%; grade 4: 1.6%).”

Source: [Heppt et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6854774/)

<a id="topic-2.2.2.1.6-17"></a>

### Liver-confined scope of percutaneous hepatic perfusion

> “Percutaneous hepatic perfusion can lead to meaningful hepatic tumour control in metastatic uveal melanoma, but its benefit is confined to liver metastases and does not address extrahepatic disease.”

Source: [van den Hoek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41785896/)

<a id="topic-2.2.2.1.6-18"></a>

### Procedural risks of hepatic perfusion: guideline statements

> “The expected benefit should be weighed against the risk of AEs (haematological complications mostly), but serious cardiovascular and thromboembolic complications may occasionally occur.”
> “The efficacy of IHP is similar to PHP, but IHP is non-repeatable and is associated with higher morbidity and mortality rates.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.1.6-19"></a>

### Grade 3 to 4 adverse events and discontinuation with melphalan percutaneous hepatic perfusion, and morbidity of isolated hepatic perfusion

> “Grades 3 and 4 TEAEs were reported in 81.1 % of the patients including grade 3 or 4 thrombocytopenia (54.7 %), leukopenia (33.7 %), anemia (32.6 %), and neutropenia (29.5 %) (Table 3 ).”
> “Treatment was discontinued for 17.9 % of the patients due to TEAEs (Table 3 ).”
> “Although IHP treats the whole liver and has shown promising tumor response rates, its use is restricted by a high risk of morbidity and mortality due to its invasive nature.”

Source: [Zager et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11249544/)

<a id="topic-2.2.2.1.6-20"></a>

### Deaths attributed to melphalan percutaneous hepatic perfusion

> “Four deaths were attributed to PHP-Mel, three in the primary PHP-Mel group, and one post-crossover to PHP-Mel from BAC.”

Source: [Hughes et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185532/)

<a id="topic-2.2.2.1.6-21"></a>

### Overall survival primary endpoint not met with isolated hepatic perfusion

> “However, the primary endpoint of OS at 24 months was not met.”

Source: [Olofsson Bagge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12140551/)

<a id="topic-2.2.2.1.6-22"></a>

### Eligibility for and morbidity of local treatment of liver metastases

> “Most patients with UMLMs have multifocal and small metastases.”
> “Around 10% of the patients are eligible for local therapy.”
> “Perioperative mortality and morbidity rates after surgery of UMLMs are ∼2% and ∼14%, respectively.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
